SUMMARY

• RYBREVANT (amivantamab-vmjw) is a low fucose, fully-human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).¹
• No studies on the use of RYBREVANT in patients with renal impairment have been conducted. Based on population pharmacokinetics (PPK) analyses, no dosage adjustment is needed for patients with mild (creatinine clearance [CrCl] ≥60 to <90 mL/min) or moderate (CrCl ≥29 to <60 mL/min) renal impairment. No data are available in patients with severe (CrCl ≥15 to <29 mL/min) renal impairment.²
• Please refer to RYBREVANT product labeling for additional information.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 06 March 2024.